OxPOS: Oxford Precision Oncology for Sarcoma

  • Research type

    Research Study

  • Full title

    OXFORD PRECISION ONCOLOGY FOR SARCOMA (OX-POS); PROSPECTIVE, LONGITUDINAL, OBSERVATIONAL STUDY WITH INTEGRATION OF NAVIFY® PATHWAY DECISION SUPPORT

  • IRAS ID

    299632

  • Contact name

    Andrew Bassim HASSAN

  • Contact email

    bass.hassan@path.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Duration of Study in the UK

    4 years, 0 months, 1 days

  • Research summary

    The question addressed in this study is whether the integration of new technologies can result in
    measurable improvements in care for participants with a rare cancer called sarcoma. These technologies
    include new cancer DNA and RNA sequencing tests that determine the basis of an individual cancer, new
    analysis of body scans and new deeper integrated analysis of all the data obtained, including cost
    effectiveness. Sarcoma patients will be invited to consent by sarcoma clinicians that are involved in their
    diagnosis and treatment in the Oxford sarcoma multidisciplinary team. All study participants (patients) will
    receive standard of care treatment throughout. They will be asked to provide; an extra blood test and use
    of excess diagnostic material for sequencing tests, consent for a study specific additional CT or ultrasound
    guided biopsy only if their sarcoma later progresses, their data in the electronic patient record including
    scan images and completion of study questionnaires. All the data collected will comply with data
    protection legislation including being pseudonymised (direct identifiers removed), but a link to direct
    identifiers remains. Depending on participant consent, study analysed data may therefore be returned for
    use by the standard of care Sarcoma MDT and communication back to the study participant and GP.
    Participants will be invited to complete standard questionnaires related to their psychological wellbeing
    and quality of life before and after a clinic appointment that will communicate the personalised study
    results. The way the results are communicated to participants will also be assessed by participant
    questionnaires after the clinic in order to improve the quality of this process. How the MDT clinicians
    actively make MDT decisions using the new data available will also be assessed using questionnaires and a
    semi-structured interview. All of the pseudonymised data is stored securely in the hospital clinical data
    warehouse and transferred for analysis using software in a secure UK based data cloud. The analysis may
    offer additional findings that are helpful to the care of each participant, and to the care of sarcoma patients
    overall.

  • REC name

    South Central - Oxford C Research Ethics Committee

  • REC reference

    22/SC/0054

  • Date of REC Opinion

    11 Mar 2022

  • REC opinion

    Favourable Opinion